Financials in USD. Standardized financial statements.
A compact view of how Timber Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $83,177 | $295,738 | $453,810 | $324,646 | $57,000 | $73,000 | $100,000 | $64,000 | $0 | $0 |
| Revenue Growth? | -71.9% | -34.8% | +39.8% | +469.6% | -21.9% | -27.0% | +56.3% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $13.30M | $6.15M | $1.50M | $3.38M | $83,000 | $250,000 | $516,000 | $237,000 | $0 | $0 |
| Gross Profit? | -$13.22M | -$5.85M | -$1.05M | -$3.06M | -$26,000 | -$177,000 | -$416,000 | -$173,000 | $0 | $0 |
| Gross Margin? | -15892.4% | -1979.4% | -230.8% | -942.0% | -45.6% | -242.5% | -416.0% | -270.3% | 0.0% | 0.0% |
| Operating Expenses? | $19.24M | $10.95M | $18.71M | $586,715 | $16.48M | $16.70M | $18.01M | $14.98M | $52,305 | $27,959 |
| Operating Income? | -$19.24M | -$10.65M | -$20.21M | -$3.64M | -$17.23M | -$23.94M | -$18.24M | -$15.59M | -$52,305 | -$27,959 |
| EBITDA? | -$19.16M | -$10.38M | -$17.78M | -$45,558 | -$17.17M | -$16.88M | -$17.98M | -$15.16M | -$52,305 | -$27,959 |
| Income Before Tax | -$19.37M | -$10.67M | -$15.08M | -$3.69M | -$17.26M | -$16.64M | -$18.40M | -$15.59M | -$52,304 | -$27,957 |
| Income Tax Expense | $7,600 | -$30,242 | $37,842 | -$156 | $2,000 | -$7.66M | $2,000 | $4,000 | $0 | $0 |
| Net Income? | -$19.38M | -$10.64M | -$15.12M | -$3.69M | -$17.26M | -$8.98M | -$18.41M | -$15.60M | -$52,304 | -$27,957 |
| EPS? | $-9.19 | $-13.15 | $-48.15 | $-29.31 | $-1340.11 | $-1567.94 | $-7710.93 | $-13030.91 | $-0.01 | $-0.00 |
| Diluted EPS? | $-9.19 | $-13.15 | $-48.15 | $-29.31 | $-1340.11 | $-1567.94 | $-7710.93 | $-13030.91 | $-0.01 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality